Remdesivir-induced symmetrical drug–related intertriginous and flexural exanthema (SDRIFE)? A case report with review of the literature

Heck, Johannes; Stichtenoth, Dirk O.; Mettin, Roland; Jöckel, J.; Bickel, Christoph; Krichevsky, Benjamin

doi:10.1007/s00228-020-02955-4

Cited by 10 publications

(8 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Wuhan, remdesivir has been seldom responsible for hypersensitivity reactions. Heck et al [5] described a SDRIFE due to remdesivir on a 67-year-old male suffering from COVID19. The likelihood of remdesivir being the culprit drug was established by applying the Naranjo Adverse Drug Reaction Probability Scale [6].…”

Section: Since the Novel Coronavirus Disease 2019 (Covid-19) Was Firs...mentioning

confidence: 99%

Remdesivir-Induced Nonimmediate Cutaneous Hypersensitivity Reaction

Galleani¹,

Bautista-Villanueva²,

Piorno³

et al. 2023

J Investig Allergol Clin

View full text Add to dashboard Cite

Intradermal tests. Palabras clave: Remdesivir. COVID-19. Hipersensibilidad no inmediata. Pruebas epicutáneas. Pruebas cutáneas en intradermorreacción. Remdesivir (GS-5734) is a prodrug of an adenosine nucleotide analogue with a potent antiviral activity against filoviruses, paramyxoviruses, pneumoviruses and coronaviruses. After being outperformed by monoclonal antibodies for the treatment of Ebola virus during the 2014-2016 Ebola outbreak in West Africa, it remained unused until the novel coronavirus disease 2019 (COVID-19) pandemic broke out. Phase III trials of remdesivir in COVID-19 were initiated on February 2020 and received an emergency use authorization by FDA [1,2]. Since its use for the treatment of COVID-19 began, adverse events were reported, such as increased hepatic enzymes, diarrhea, and skin reactions, among others [3]. We report a case of maculopapular exanthema induced by remdesivir confirmed by patch tests (PTs) and intradermal skin tests (IDTs).A 75-year-old woman with a medical history of asthma and obstructive sleep apnea-hypopnea syndrome was admitted to the hospital due to double pneumonia and respiratory failure caused by severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) infection. Because of a lack of response to high-flow oxygen, continuous positive airway pressure and intravenous bolus of corticosteroids, remdesivir treatment

show abstract

Section: Since the Novel Coronavirus Disease 2019 (Covid-19) Was Firs...mentioning

confidence: 99%

Remdesivir-Induced Nonimmediate Cutaneous Hypersensitivity Reaction

Galleani¹,

Bautista-Villanueva²,

Piorno³

et al. 2023

J Investig Allergol Clin

View full text Add to dashboard Cite

show abstract

“…Several drugs are reported to be the causative agents of SDRIFE. [3][4][5] Among them, beta-lactam antibiotics are the commonest triggers. PPIs are among the most commonly prescribed drugs with good tolerability.…”

Section: Main Textmentioning

confidence: 99%

“…Several drugs are reported to be the causative agents of SDRIFE 3–5 . Among them, beta‐lactam antibiotics are the commonest triggers.…”

Section: Main Textmentioning

confidence: 99%

Three cases of symmetrical drug‐related intertriginous and flexural exanthema (SDRIFE) induced by proton‐pump inhibitors

et al. 2022

View full text Add to dashboard Cite

Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE), previously termed drug-related baboon syndrome, is an uncommon drug eruption.It is characterized by symmetrical erythema involving the gluteal and/or inguinal area in association with one other intertriginous area in the absence of systemic involvement. It typically develops a few hours to days after drug exposure. The diagnosis is based on clinical presentation and drug history. The treatment consists mainly of withdrawal of the causative agent; corticosteroids (topical or systemic) are prescribed to accelerate the resolution. We present three cases that appeared after proton-pump inhibitors (PPIs) intake. K E Y W O R D Scutaneous drug eruptions, proton-pump inhibitors (PPIs), symmetrical drug-related intertriginous and flexural exanthema (SDRIFE)

show abstract

“…While one of them was on treatment with piperacillin/tazobactam, azithromycin, hydroxychloroquine and oseltamivir while the other developed SDRIFE following remdesivir. 5,11 However, it is not clear whether the rash is associated with COVID-19 or the drugs in these cases. In our third patient, favipiravir is more likely the culprit because the rash developed on the third day of treatment.…”

Section: Observation Lettermentioning

confidence: 99%